Triple‐negative breast cancer (TNBC) is still the most aggressive cancer in women.
Combination chemotherapy holds great potential for cancer therapy; however, the off‐target …

Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-
positive breast cancer patients, and is considered as a keystone of systemic cancer therapy …

Breast cancer, with around 2 million new cases in 2019, is the second most common cancer
worldwide and the second leading cause of cancer death among females. The aim of this …

Background Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of
breast cancer with a bad prognosis. Chemotherapy is still the standard of care for TNBC …

Despite the advances in cancer treatment in recent years, the development of resistance to
cancer therapy remains the biggest hurdle towards curative cancer treatments. Therefore …

Steroid hormone signaling induces vast gene expression programs which necessitate the
local formation of transcription factories at regulatory regions and large-scale alterations of …

Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher
propensity to earlier metastases, and shorter survival after recurrence compared with other …

Abstract PD-L1/PD-1 blockade therapy shows durable responses to triple-negative breast
cancer (TNBC), but the response rate is low. CD155 promotes tumor metastasis intrinsically …

Purpose Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast
cancer that is frequently treated with chemotherapy. However, many patients exhibit either …

Due to a special pathological type of triple-negative breast cancer (TNBC) and the lack of
expression of the estrogen receptor (ER), progesterone receptor (PR), and human …